Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE)

CUSIP: 00439U104

Q4 2024 13F Holders as of 31 Dec 2024

Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
16,654,455
Total 13F shares
2,087,877
Share change
+1,128,274
Total reported value
$7,835,456
Price per share
$3.74
Number of holders
15
Value change
+$4,246,540
Number of buys
12
Number of sells
1

Quarterly Holders Quick Answers

What is CUSIP 00439U104?
CUSIP 00439U104 identifies GRCE - Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) as of Q4 2024

As of 31 Dec 2024, Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) was held by 15 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 2,087,877 shares. The largest 10 holders included ADAR1 Capital Management, LLC, AIGH Capital Management LLC, BANK OF AMERICA CORP /DE/, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, NATIONAL BANK OF CANADA /FI/, MORGAN STANLEY, Tower Research Capital LLC (TRC), and Royal Bank of Canada. This page lists 15 institutional shareholders reporting positions in this security for the Q4 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.